



Validity of Biopolymer Engineering's Beta Glucan Patents Recognized in Settlement of Patent Infringement Lawsuit

EAGAN, MN – June 19, 2003 – Biopolymer Engineering, Inc., announced today that it has reached a settlement in its patent infringement lawsuit against Levapan S.A. and Savoury Systems International Inc.

Under the terms of the settlement agreement Biopolymer Engineering has filed in U.S. District Court in Minnesota, Levapan and Savoury Systems International recognize and agree to the validity of Biopolymer Engineering's patents relating to beta 1,3/1,6 glucan and agree not to sell yeast-based beta 1,3/1,6 glucan products in the United States.

"We are pleased to have reached a successful settlement to this patent lawsuit that recognizes the validity of our beta glucan patents and protects our markets," said Richard G. Mueller, Biopolymer Engineering President and Chief Executive Officer. "We appreciated the efforts of Levapan and Savoury Systems International in quickly settling this lawsuit and look forward to a strong supplier relationship."

Biopolymer Engineering, Inc. is a biotechnology company that is pioneering carbohydrate technologies to improve health through immune enhancement. Founded in 1997 and based in Eagan, Minnesota, the company owns more than 200 U.S. and international patents protecting the composition, manufacturing and applications of its yeast beta 1,3 glucan compounds and products. The company's application patents include use of yeast beta 1,3 glucans in pharmaceuticals, dietary supplements, cosmetics, animal feed and nutrition and functional foods.

For more information, visit www.biopolymer.com or contact:

David Walsh
Biopolymer Engineering, Inc.
651-675-0300
dwalsh@biopolymer.com